Journal of Scleroderma and Related Disorders, published by SAGE Publications Ltd, stands as a key platform dedicated to advancing the understanding of scleroderma and related autoimmune disorders. With its ISSN of 2397-1983 and E-ISSN of 2397-1991, this esteemed journal has been contributing to the field since its inception in 2016 and continues to attract attention with its convergence period extending to 2024. The journal operates with an open access policy, thus enhancing the visibility and accessibility of research findings for healthcare professionals, researchers, and students worldwide. Recognized for its significant impact, it holds a Q3 quartile ranking in Immunology and Q2 rankings in Immunology and Allergy and Rheumatology in 2023, showcasing its relevance in these critical fields. Furthermore, the journal has achieved commendable Scopus rankings, positioning it firmly within the top echelons of its categories, particularly in Medicine - Rheumatology (#33/73, 55th percentile). With its comprehensive scope, the Journal of Scleroderma and Related Disorders plays a pivotal role in disseminating vital research that can influence treatment strategies and improve patient care for those suffering from scleroderma and its related conditions.

Translational Neurodegeneration, an esteemed journal in the field of neuroscience, is published by BMC and has been an open access platform since 2012, delivering high-quality research from its base in the United Kingdom. With an impressive impact factor reflecting its significant contributions, this journal focuses on critical advancements in cellular and molecular neuroscience, cognitive neuroscience, and clinical neurology, boasting a Q1 ranking across all these categories as of 2023. Researchers and professionals benefit from its extensive reach, characterized by exceptional Scopus rankings that place it in the top percentile of its field. The journal serves as a vital resource for academics and healthcare practitioners alike, aiming to bridge the gap between laboratory discoveries and clinical applications, thereby enhancing understanding and treatment of neurodegenerative diseases. With its commitment to open access, Translational Neurodegeneration ensures that its published research is accessible to a global audience, promoting collaboration and knowledge exchange within the scientific community.

NEUROLOGIC CLINICS, published by W B SAUNDERS CO-ELSEVIER INC, stands as a leading journal in the field of clinical neurology, boasting an impressive impact factor that reflects its significant contributions to neurological research and clinical practice. With an ISSN of 0733-8619 and E-ISSN of 1557-9875, this journal provides a critical platform for the dissemination of innovative research, case studies, and reviews focusing on various aspects of neurology, from diagnosis to treatment interventions. As part of its commitment to advancing the understanding of neurological disorders, NEUROLOGIC CLINICS is categorized in the Q2 quartile for Neurology (clinical) in 2023, indicating its robust standing within the academic community. It is recognized for its rigorous peer-review process and is indexed in Scopus, ranking #147 out of 400 in its field with a notable 63rd percentile. The journal, which dates back to 1983 and continues to publish vital findings up to 2024, is an invaluable resource for researchers, healthcare professionals, and students dedicated to enhancing their knowledge and clinical skills in neurology. Subscribe now to stay abreast of current advancements and expand your expertise in this dynamic field.

Canadian Journal of Neurological Sciences, published by Cambridge University Press, stands as a reputable source of knowledge in the field of neurology, dedicated to advancing research and clinical practice. With an ISSN of 0317-1671 and an E-ISSN of 2057-0155, this journal has been a cornerstone for the exchange of ideas since its inception in 1974 and will continue to cater to the academic community until 2024. Recognized in the top quartile (Q2) in various categories including Medicine (miscellaneous) and Neurology (clinical), its articles engage a broad audience, ranging from established researchers to students seeking to deepen their understanding of neurological sciences. Although the journal is not an open-access publication, it provides vital insights and research findings that contribute significantly to its fields. With a Scopus rank of #183 in clinical neurology and a percentile ranking that reflects its commendable standing, the Canadian Journal of Neurological Sciences is indispensable for those committed to the exploration and treatment of neurological disorders.

Neurology and Therapy, published by SPRINGER LONDON LTD, stands as a pivotal platform for researchers and practitioners in the field of neurology and its therapeutic applications. This Open Access journal, active since 2012, facilitates the dissemination of innovative studies and cutting-edge findings aimed at improving neurological health. With an impressive ranking in the 2023 Scopus Rankings, where it holds a Q2 category in Neurology and a Q1 category in Clinical Neurology, it underscores its prominence in advancing neurological research. The journal's intriguing scope encompasses a wide-ranging exploration of neurological disorders, treatment methodologies, and healthcare strategies, making it a valuable resource for those vested in enhancing patient outcomes. With an appealing average impact factor, readers are encouraged to dive into the latest advancements and engage with the scholarly discussions that are shaping the future of neurology.

Neurology International is a prestigious open-access journal published by MDPI that has been making significant contributions to the field of neurology since its establishment in 2009. With its ISSN 2035-8377, this journal is committed to disseminating high-quality, peer-reviewed research that addresses a wide range of clinical topics in neurology. Operating out of Basel, Switzerland, the journal holds a respectable Q2 ranking in the clinical neurology category as of 2023, indicating its influence and dedication to advancing scientific knowledge. Researchers and practitioners alike will find value in its comprehensive articles, which are readily accessible to a global audience, facilitating the sharing of innovative findings and clinical practices. As it converges towards 2024, Neurology International continues to provide a vital platform for scholarly discourse, aiming to improve patient outcomes and enhance our understanding of neurological disorders.

ACTA NEUROLOGICA BELGICA is a leading academic journal published by Springer Heidelberg, dedicated to advancing the field of neurology and medicine. With an ISSN of 0300-9009 and E-ISSN 2240-2993, this journal has been a vital resource since its inception, contributing significantly to neurological research and clinical practice. It holds a respectable impact factor with categories spanning from Q2 in Medicine (miscellaneous) to Q3 in Neurology (clinical) as of 2023, indicating its prominence in the scientific community. The journal's extensive coverage since 1959 enhances its historical relevance, while its ongoing publication until 2024 ensures the latest developments are readily accessible. Researchers and practitioners can benefit from its rigorous peer-reviewed articles, which are crucial for staying current in this rapidly evolving discipline. As a scholarly platform, ACTA NEUROLOGICA BELGICA plays a pivotal role in disseminating knowledge and fostering innovation in neurology, making it a must-read for professionals, students, and anyone involved in the field.

NeuroImage-Clinical is a premier open access journal published by Elsevier Science Ltd, dedicated to advancing the field of clinical neuroimaging and its applications in a variety of neurological disorders. With an ISSN of 2213-1582, this journal has established itself as a leading source of innovative research since its inception in 2012, now continuing through 2024. Recognized for its high impact, it occupies the top quartile (Q1) in prestigious categories such as Cognitive Neuroscience, Neurology, and Radiology, affirming its relevance in clinical and research settings. Its Scopus rankings further exemplify its significant contribution to the disciplines of Radiology and Neurology, consistently placing it among the top tiers of journals in these fields. This journal not only provides critical insights for researchers and professionals but also serves as a valuable resource for students, fostering an understanding of the complexities in neuroimaging techniques and their implications for patient care. With open access options ensuring broad dissemination of knowledge, NeuroImage-Clinical plays a pivotal role in enhancing collaboration and innovation within the global neuroscience community.

NEUROLOGIST, an esteemed journal published by Lippincott Williams & Wilkins, serves as a vital resource in the fields of Neurology and Medicine. With an ISSN of 1074-7931 and an E-ISSN of 2331-2637, this journal has been dedicated to advancing the understanding of neurological disorders since its inception in 1996, with continual contributions through 2024. Achieving a respectable Q3 rank in both Medicine (miscellaneous) and Neurology (clinical), it provides an essential platform for disseminating innovative research and clinical studies. Although it is not an open-access publication, NEUROLOGIST promotes a rich exchange of ideas and findings for researchers, healthcare professionals, and students alike, helping to bridge the gaps in neurological research and practice. The journal is recognized for its commitment to enhancing clinical practice and research methodology, making it a valuable asset for anyone engaged in the dynamic field of neurology.

Neurodegenerative Disease Management is a distinguished journal published by FUTURE MEDICINE LTD, focusing on the pivotal issues surrounding the management of neurodegenerative diseases. Since its inception in 2014, this journal has emerged as a significant resource within the fields of medicine and neurology, currently holding a respected position with a Q2 category ranking in Medicine (miscellaneous) and Q3 in Neurology (clinical) for 2023. With an ISSN of 1758-2024 and E-ISSN 1758-2032, the journal provides a platform for the dissemination of innovative research, clinical practices, and advancements in treatment strategies for conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. The journal is particularly committed to enhancing knowledge sharing among researchers, health professionals, and students, contributing to the collective effort in combatting neurodegenerative diseases. Though not open access, its articles are meticulously curated to ensure high-quality, impactful contributions to the field, making it an essential reference for those engaged in neurology and related disciplines.